Medipharm Labs Corp (LABS) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.022x

Based on the latest financial reports, Medipharm Labs Corp (LABS) has a cash flow conversion efficiency ratio of -0.022x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-778.00K ≈ $-562.79K USD) by net assets (CA$35.10 Million ≈ $25.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LABS cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Medipharm Labs Corp - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Medipharm Labs Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Medipharm Labs Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Medipharm Labs Corp ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Logic Instrume
PA:ALLOG
-0.125x
Mirasol Resources Ltd
V:MRZ
0.915x
Calgro M3 Holdings Ltd
JSE:CGR
-0.059x
Longeveron LLC
NASDAQ:LGVN
-0.273x
OYAK Yatirim Ortakligi AS
IS:OYAYO
-0.012x
Four Seasons Education Cayman
NYSE:FEDU
N/A
Allied Industrial Ltd
TWO:4702
-0.006x
Helium Evolution Inc
V:HEVI
-0.016x

Annual Cash Flow Conversion Efficiency for Medipharm Labs Corp (2016–2025)

The table below shows the annual cash flow conversion efficiency of Medipharm Labs Corp from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Medipharm Labs Corp stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CA$35.81 Million
≈ $25.91 Million
CA$-5.50 Million
≈ $-3.98 Million
-0.154x -36.54%
2024-12-31 CA$43.18 Million
≈ $31.24 Million
CA$-4.86 Million
≈ $-3.52 Million
-0.113x +51.65%
2023-12-31 CA$53.01 Million
≈ $38.34 Million
CA$-12.34 Million
≈ $-8.93 Million
-0.233x +18.87%
2022-12-31 CA$56.01 Million
≈ $40.51 Million
CA$-16.07 Million
≈ $-11.62 Million
-0.287x -80.55%
2021-12-31 CA$83.15 Million
≈ $60.15 Million
CA$-13.21 Million
≈ $-9.56 Million
-0.159x +67.01%
2020-12-31 CA$78.41 Million
≈ $56.72 Million
CA$-37.77 Million
≈ $-27.32 Million
-0.482x -150.20%
2019-12-31 CA$131.23 Million
≈ $94.93 Million
CA$-25.27 Million
≈ $-18.28 Million
-0.193x +51.76%
2018-12-31 CA$27.84 Million
≈ $20.14 Million
CA$-11.11 Million
≈ $-8.04 Million
-0.399x -410.70%
2017-12-31 CA$-2.12 Million
≈ $-1.54 Million
CA$166.00K
≈ $120.08K
-0.078x +69.21%
2016-12-31 CA$215.46K
≈ $155.86K
CA$-54.69K
≈ $-39.56K
-0.254x --

About Medipharm Labs Corp

TO:LABS Canada Drug Manufacturers - Specialty & Generic
Market Cap
$23.05 Million
CA$31.86 Million CAD
Market Cap Rank
#24670 Global
#951 in Canada
Share Price
CA$0.08
Change (1 day)
+7.14%
52-Week Range
CA$0.06 - CA$0.09
All Time High
CA$7.17
About

MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It a… Read more